2. Induced Disease Models Products Others Metabolic Enzyme/Protease
  3. Cancer Models Environmental Pollutants Endogenous Metabolite
  4. Lung Cancer Models Skin Cancer Models
  5. Benzo[a]pyrene

Benzo[a]pyrene  (Synonyms: 3,4-Benzopyrene)

Cat. No.: HY-107377 Purity: 99.98%
COA
SDS
Handling Instructions Technical Support

Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.

For research use only. We do not sell to patients.

CAS No. : 50-32-8

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
500 mg In-stock
1 g In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Benzo[a]pyrene:

Benzo[a]pyrene Related Antibodies

Top Publications Citing Use of Products

    Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118.  [Abstract]

    SYTOX Green staining to visualize NETs formation in neutrophils after Benzo[a]pyrene (BaP) (10 μM; 24 h) exposure.

    Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118.  [Abstract]

    Western blot analysis detecting H3Cit levels in neutrophils treated with different Benzo[a]pyrene (BaP) (5-10 μM; 24 h) concentrations. Benzo[a]pyrene (BaP) increased NETs generation in a dose-dependent manner.

    Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2025 Dec 29:170:116118.  [Abstract]

    The levels of MPO-DNA complexes in the neutrophil culture supernatants were measured following transfection with siRNAs targeting PADI4. Benzo[a]pyrene (BaP) (100 μg/mL; 24 h) markedly promoted NETs formation in HL60-induced neutrophil models.

    Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Cancer Cell Int. 2024 Jan 17;24(1):33.  [Abstract]

    Representative images showed gross morphology of stomachs harboring Benzo[a]pyrene (BaP)-induced tumors (50 mg/kg; i.g.; twice a week for 6 weeks) from wildtype and Usp29−/− mice.

    Benzo[a]pyrene purchased from MedChemExpress. Usage Cited in: Neurotoxicology. 2021 Sep:86:78-84.  [Abstract]

    Under all lighting conditions, Benzo[a]pyrene (BaP) (5 μM; from 5 hpf until 5 dpf) significantly reduced the activity level of zebrafish compared to the control group.

    View All Endogenous Metabolite Isoform Specific Products:

    View All Isoforms
    Human Endogenous Metabolite Microbial Metabolite

    • Biological Activity

    • Protocol

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Benzo[a]pyrene shows lung carcinogenicity in animal models, and it is frequently used in chemoprevention studies.

    Cellular Effect
    Cell Line Type Value Description References
    MCF7 EC50
    2.7 μM
    Compound: 2
    Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay
    Agonist activity at aryl hydrocarbon receptor in human MCF7 cells after 24 hrs CYP1A1-dependent EROD assay
    		[PMID: 20060304]
    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Benzo[a]pyrene (B[a]P) can be used to create lung tumor models. The bioavailability of Benzo[a]pyrene in rats is 10%, with a half-life of 16.6 hours. In female A/J mice, compared to the vehicle group, the 1.0 mg Benzo[a]pyrene treatment group shows statistically significant differences at 7 weeks, indicating that Benzo[a]pyrene-induced lung tumorigenesis is dose-dependent. The incidence of hyperplasia in female mice treated with 0.25, 0.50, and 1.0 mg Benzo[a]pyrene is significantly higher than in the vehicle group, and the adenoma incidence in the 1.0 mg Benzo[a]pyrene group is also significantly increased. Additionally, the multiplicity of hyperplasia in the 0.50 or 1.0 mg Benzo[a]pyrene treatment groups and the multiplicity of adenomas in the 1.0 mg group are significantly higher than in the vehicle group. Benzo[a]pyrene significantly increases the incidence of hyperplasia and adenomas in female A/J mice in a dose-dependent manner. On average, Benzo[a]pyrene induces the formation of 9.38±1.75 tumors, with an average tumor burden of 19.53±3.81 mm3. Administration of Benzo[a]pyrene also significantly decreases the levels of cAMP in the tumor and surrounding lung tissue and increases the expression levels of the PDE4D gene[1][2].

    Induction of Lung cancer[4][5]
    Background
    Benzo[a]pyrene can covalently bind to DNA to form DNA adducts, which can lead to DNA damage and mutation. These conjugations can interfere with DNA replication and repair processes, causing genetic mutations and chromosomal abnormalities that lead to tumor formation.
    Specific Modeling Methods
    Mice: Swiss albino mice • 8-10 weeks old • male
    Administration: 50 mg/kg• p.o. • twice a week (1st and 4th day) for four successive weeks
    Note
    (1) Benzo[a]pyrene was dissolved in olive oil.
    (2) All procedures were performed at temperatures ranging between 0 and 4°C.
    (3) At the end of the experimental period, the animals were sacrificed. Lung tissues were isolated, washed in ice cold 1.15 % KCl and homogenized.
    Modeling Indicators
    Molecular changes:The contents of TNF-α, IL-6, COX-2 and NF-ΚB were detected.
    Histological analysis:Toluidine blue staining was used to detect the number of mast cells.
    Correlated Product(s): Capsaicin (HY-10448)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molecular Weight

    252.31

    Formula

    C20H12
    CAS No.
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    C12=C(C=C3)C=C(C=CC=C4)C4=C1C=CC5=CC=CC3=C25
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Store at room temperature 3 years

    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : 16.67 mg/mL (66.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.9634 mL 19.8169 mL 39.6338 mL
    5 mM 0.7927 mL 3.9634 mL 7.9268 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 1.67 mg/mL (6.62 mM); Clear solution

      This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 1.67 mg/mL (6.62 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  1% CMC-Na/saline water

      Solubility: 5 mg/mL (19.82 mM); Suspended solution; Need ultrasonic and warming and heat to 50°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.98%

    SDS (761 KB)

    COA (253 KB)

    Handling Instructions (2659 KB)
    References
    Animal Administration
    [2]

    Female A/J mice are randomized into eight groups (n=8): (i) control; (ii)Benzo[a]pyrene (B(a)P)+vehicle (methocel); (iii) Benzo[a]pyrene+roflumilast 1 mg/kg; (iv) Benzo[a]pyrene+roflumilast 5 mg/kg; (v) Benzo[a]pyrene+aerozolie phosphate-buffer saline (PBS); (vi) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL; (vii) Benzo[a]pyrene+aerosolized budesonide 2.25 mg/mL+roflumilast 1 mg/kg; and (viii) Benzo[a]pyrene+aerosolize budesonide 2.25 mg/mL+roflumilast 5 mg/kg groups. A single dose of Benzo[a]pyrene in corn oil is given intraperitoneally once at 100 mg/kg body weight. Roflumilast (1 or 5 mg/kg) is started 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (3 days/week) via oral gavage. Mice in the Benzo[a]pyrene+vehicle group are treated with an equal volume of methocel as solvent control. Aerosolizing budesonide is administrated by inhaling route as an aerosol at a dose of 2.25 mg/mL for 2 min per application at 2 weeks after Benzo[a]pyrene. It is continued for 26 weeks (5 days/week). PBS is also used as solvent control by inhaling route after Benzo[a]pyrene administration in the Benzo[a]pyrene+PBS group. Mice are killed at 28 weeks after exposure to Benzo[a]pyrene. Their lungs are excised and stored at -70 °C[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.9634 mL 19.8169 mL 39.6338 mL 99.0845 mL
    5 mM 0.7927 mL 3.9634 mL 7.9268 mL 19.8169 mL
    10 mM 0.3963 mL 1.9817 mL 3.9634 mL 9.9084 mL
    15 mM 0.2642 mL 1.3211 mL 2.6423 mL 6.6056 mL
    20 mM 0.1982 mL 0.9908 mL 1.9817 mL 4.9542 mL
    25 mM 0.1585 mL 0.7927 mL 1.5854 mL 3.9634 mL
    30 mM 0.1321 mL 0.6606 mL 1.3211 mL 3.3028 mL
    40 mM 0.0991 mL 0.4954 mL 0.9908 mL 2.4771 mL
    50 mM 0.0793 mL 0.3963 mL 0.7927 mL 1.9817 mL
    60 mM 0.0661 mL 0.3303 mL 0.6606 mL 1.6514 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Benzo[a]pyrene Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Benzo[a]pyrene50-32-83,4-BenzopyreneEnvironmental PollutantsEndogenous MetaboliteEnvironmental ContaminantsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Benzo[a]pyrene
    Cat. No.:
    HY-107377
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (761 KB) Français - FR (761 KB) Deutsch - DE (761 KB) Norwegian - NO (761 KB) Español - ES (761 KB) Swedish - SV (761 KB) Italian - IT (761 KB) Korean - KR (761 KB) Portuguese - PT (761 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.